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Late-onset Alzheimer disease (AD) is a chronic and 
progressive neurodegenerative disorder clinically 
characterized by memory loss and cognitive decline. 
Representative histopathological findings in AD brain 
include extracellular amyloid-β (Aβ) plaques, intracellular  
 
neurofibrillary tangles composed of hyperphosphorylated 
tau, and a continuous loss of neurons. According to the 
‘amyloid cascade hypothesis’, Aβ deposition is the cause 
of AD [1]. However, in the ‘mitochondrial cascade 
hypothesis’, the origin of AD is a defect in the oxidative 
phosphorylation (OXPHOS) system [2]. Interestingly, 
bioenergetics and Aβ appear to be closely related. Thus, 
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Many patients suffering late-onset Alzheimer disease show a deficit in respiratory complex IV activity. The de 
novo pyrimidine biosynthesis pathway connects with the mitochondrial respiratory chain upstream from 
respiratory complex IV. We hypothesized that these patients would have decreased pyrimidine nucleotide 
levels. Then, different cell processes for which these compounds are essential, such as neuronal membrane 
generation and maintenance and synapses production, would be compromised. Using a cell model, we show 
that inhibiting oxidative phosphorylation function reduces neuronal differentiation. Linking these processes to 
pyrimidine nucleotides, uridine treatment recovers neuronal differentiation. To unmask the importance of 
these pathways in Alzheimer disease, we firstly confirm the existence of the de novo pyrimidine biosynthesis 
pathway in adult human brain. Then, we report altered mRNA levels for genes from both de novo pyrimidine 
biosynthesis and pyrimidine salvage pathways in brain from patients with Alzheimer disease. Thus, uridine 
supplementation might be used as a therapy for those Alzheimer disease patients with low respiratory complex 
IV activity. 
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Aβ can reduce OXPHOS function and OXPHOS 
deficiency can increase Aβ production [3]. 
 
OXPHOS is much more than an energy-generating 
cellular pathway [4]. OXPHOS dysfunction can affect 
many biochemical routes, among them the de novo 
pyrimidine biosynthesis. This process requires three 
proteins: CAD, named after its three enzyme 
activities, carbamoyl-phosphate synthetase, aspartate 
transcarbamylase and dihydroorotase; DHODH, 
dihydroorotate dehydrogenase; and UMPS, which 
enzyme activities are orotate phosphoribosyltransferase 
and orotidine-5′-phosphate decarboxylase (Figure 1). 
DHODH is located in the mitochondrial inner 
membrane and directly transfers electrons to the 
OXPHOS electron transport chain (ETC) via 
coenzyme Q10 [5]. A reduction of electron transport 
downstream coenzyme Q10 would slow down DHODH 
activity and the de novo pyrimidine biosynthesis. 
 
Pyrimidine nucleotides are required for the synthesis of 




Figure 1. Oxidative phosphorylation system (OXPHOS) and 
biochemical pathways for pyrimidine nucleotide synthesis. 
OM, IMS, IM, and M code for mitochondrial outer membrane, 
intermembrane space, mitochondrial inner membrane, and 
mitochondrial matrix, respectively; ETC, electron transport chain; 
CI, CIII, CIV, CV and Cyt c code for respiratory complexes I, III, IV, 
ATP synthase and cytochrome c, respectively; Q, coenzyme Q10; 
NADH and NAD+, reduced and oxidized forms of nicotinamide 
adenine dinucleotide; H+, protons; e-, electrons; ADP, ATP and Pi, 
adenosine diphosphate, adenosine triphosphate, and inorganic 
phosphate; H2O, water; O2, oxygen; CAD, carbamoyl phosphate 
synthetase, aspartate transcarbamylase, dihydroorotase; DHODH, 
dihydroorotate dehydrogenase; UMPS, uridine monophosphate 
synthase; HCO3-, bicarbonate; Gln, glutamine; Asp, aspartate; DHO, 
dihydroorotate; O, orotate; PRPP, phosphoribosyl 5’-
pyrophosphate; UMP, uridine monophosphate; CMP, cytidine 
monophosphate; CTP, cytidine triphosphate; UCK2, uridine cytidine 
kinase 2. 
components, such as glycoproteins, glycolipids, and 
phospholipids. As proliferating cells need to duplicate 
their genomes and other cell components like biological 
membranes, they depend on high concentrations of 
pyrimidine nucleotides. Then, the de novo pyrimidine 
biosynthesis pathway is indispensable for these cells. 
However, differentiated cells do not divide themselves 
or replicate their genomes. Hence, it is generally 
considered that the activity of de novo route is low in 
these cells and they satisfy their need for pyrimidine 
nucleotides through the salvage pathway [5]. In this 
process, the uridine-cytidine kinase 2 (UCK2) 
phosphorylates uridine and cytidine nucleosides to 
produce UMP and CMP [6]. 
 
Neurons are post-mitotic, differentiated cells. 
Neuronal differentiation includes the formation of 
axons and dendrites and the maintenance of the 
neuron’s vastly expanded surface. These events 
require a continuous membrane synthesis, even in 
adult’s post-mitotic neurons [7]. Moreover, it has 
been observed that highly elaborate axonal 
arborization of neurons greatly increases their 
baseline energy demands, rendering neurons more 
vulnerable to perturbations of mitochondrial function 
pathways [8]. We had previously hypothesized that an 
OXPHOS dysfunction in AD patients can secondarily 
affect de novo pyrimidine biosynthesis and the plasma 
membrane remodeling [9]. This might explain the 
alterations in composition and structure of neuronal 
membranes linked to loss of synapsis that precede 
neuronal loss in AD patients [10]. Therefore, 
pyrimidine nucleoside supplementation could be used 
as a therapeutic agent in AD.  
 
RESULTS AND DISCUSSION 
 
OXPHOS dysfunction impairs neuronal 
differentiation through altered de novo pyrimidine 
biosynthesis 
 
Expression of enzymes from pathways for pyrimidine 
nucleotide synthesis in neurons differentiated from 
neuroblastoma SH-SY5Y cells  
To check a potential effect of the OXPHOS dysfunction 
on neuronal pyrimidine nucleotide synthesis, we used 
the human neuroblastoma SH-SY5Y cell line as a 
model. This cell line has frequently been used to study 
AD-related issues. In fact, considering ‘SH-SY5Y’ and 
‘Alzheimer’s’ terms, more than 1,400 publications 
appear in PubMed database. These cells can be 
differentiated into dopaminergic neurons. They express 
βIII-tubulin (TUBB3), a neuronal marker, and tyrosine 
hydroxylase (TH), a dopaminergic marker (Figure 2A–
2I). Neuronal differentiation is also accompanied by an 
increase in oxygen consumption (Figure 2J). 
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Proliferating cells express both DHODH and UCK2 
mRNAs (Figure 2K). Levels are very similar to those 
reported in the human protein atlas webpage 
(https://www.proteinatlas.org/). DHODH mRNA levels 
were approximately five times lower than those for 
UCK2 mRNA. Neuronal differentiation did not modify 
mRNA values. The UCK2 protein was not detected in 
proliferating cells, although CAD and DHODH proteins 
were found (Figure 2L–2N). As UCK2 was previously 
reported in proliferating SH-SY5Y cells [11], we ruled 
out a general lack of pyrimidine salvage pathway in 
these cells. Perhaps the anti-UCK2 antibody was not 
sensitive enough. In fact, we needed 10 μg of a 
commercial enzyme to obtain a faint band in the 
Western blot. Additionally, we confirmed the presence 
of CAD and DHODH, but no UCK2, in these post-
mitotic cells, i.e. neuron-differentiated SH-SY5Y cells 
(Figure 2L–2N).  
 
Neuronal differentiation after DHODH inhibition 
As previously commented upon, de novo pyrimidine 
biosynthesis is relevant for proliferating cells. Orally 
administered leflunomide is almost completely 
converted into its active metabolite teriflunomide and, 
inhibiting DHODH, it decreases pyrimidine nucleotide 
availability and cell proliferation. Because of this, it has 
been used for treatment of rheumatoid arthritis and it is 
also a potent anticancer drug [12]. During patient 
treatment, teriflunomide steady-state plasma 
concentrations of 200 μM can be reached [13]. We 
observed that leflunomide 100 μM largely reduces cell 
proliferation of human neuroblastoma SH-SY5Y cells 
(Figure 3A). 
 
According to our hypothesis, de novo pyrimidine 
biosynthesis pathway is also important for neurons. To 
revel its role in these cells, we studied the leflunomide 
effect on neuronal differentiation. Leflunomide 100 μM 
prevents an increase in TUBB3 and TH levels (Figure 
3B). It has been shown that uridine can completely 
overcome growth inhibition by leflunomide [14]. 
However, uridine 200 or 800 μM were not able to 
prevent the effect of leflunomide on neuronal 
differentiation (Figure 3B).  
 
The additional inhibition of other cell functions by 
leflunomide, besides its effect on the de novo 
pyrimidine biosynthesis pathway, might be the reason 
why uridine has no effect in the maintaining neuronal 
differentiation [12]. In human cells, leflunomide 
reduces the mitochondrial inner membrane potential 
[15]. Mitochondrial inner membrane potential is 
generated by the electron flow through the respiratory 
chain, and this electron flow is associated with oxygen 
consumption. To determine the leflunomide effect on 
oxygen consumption of neuroblastoma SH-SY5Y cells, 
we tested different leflunomide concentrations. 
Leflunomide 100 μM reduces oxygen consumption to a 
residual 33.5 % (Figure 3C). Supporting our results, it 
has been reported that leflunomide, or its metabolite 
teriflunomide, decreased oxygen consumption in mouse 
and human cells [13, 16–20]. These results suggest that 
an important part of oxygen consumption and energy 
production in proliferating cells is due to pyrimidine 
biosynthesis. DHODH knockdown diminished 
mitochondrial ATP production and inner membrane 
potential in mouse and human cells [21, 22]. 
Leflunomide causes mitochondrial proliferation in 
human cells [15], suggesting a compensatory response. 
Moreover, externally added uridine to the culture media 
did not improve the mitochondrial inner membrane 
potential and did not prevent mitochondrial 
proliferation, despite that uridine normalizes the cell 
cycle progression [15]. Uridine 200 μM do not recover 
oxygen consumption of leflunomide-treated cells 
(Supplementary Figure 1). Similarly, it was reported 
that uridine had no protective effect against tamoxifen-
induced impairment to mitochondrial respiration [23]. 
 
Neuronal differentiation after OXPHOS inhibition 
The OXPHOS dysfunction due to leflunomide might be 
responsible for the reduced neuronal differentiation of 
neuroblastoma SH-SY5Y cells. Because leflunomide 
also acts on other cell targets [12], we selected the CIV 
inhibitor potassium cyanide (KCN) that presumably 
does not act on these other leflunomide targets. KCN 10 
μM or 25 μM decrease oxygen consumption in 
neuroblastoma SH-SY5Y cells to a residual 78 and 62 
%, respectively (Figure 4A). It had been previously 
shown that KCN abolished DHO-induced oxygen 
consumption in mouse cells and mitochondria from 
different rat tissues [16, 24], confirming that OXPHOS 
CIV inhibition affected the de novo pyrimidine 
biosynthesis pathway. Moreover, in the human 
neuroblastoma SH-SY5Y cell line, KCN 10 μM and 25 
μM do not affect cell proliferation (Figure 4B). 
 
Neuroblastoma SH-SY5Y cells were cultured with 
KCN 10 μM to analyze the effect of OXPHOS 
dysfunction on neuronal differentiation. These cells do 
not show increased TUBB3 and TH levels (Figure 4C). 
Supporting our results, it was previously reported that 
KCN significantly inhibited the dopaminergic neuronal 
differentiation of neural progenitor cells, derived from 
human induced pluripotent stem cells [22]. Hence, this 
compound, by reducing respiratory chain activity, 
prevents dopaminergic neuronal differentiation.  
 
In MDA231 human breast cancer cells, it has been 
shown that de novo pyrimidine synthesis pathway is 
depressed under low energy conditions, supposedly to 
reduce ATP-consumption [25]. To determine if that 
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Figure 2. Expression of selected genes from pyrimidine nucleotide synthesis pathways in human neuroblastoma SH-SY5Y 
cells. (A, B) Representative optic microscopy images of (A) undifferentiated and (B) neuron-differentiated SH-SY5Y cells. White arrows point 
to neurites. (C, D) Representative immunofluorescence microscopy images of anti-TUBB3 stained (C) undifferentiated and (D) neuron-
differentiated SH-SY5Y cells. Inset: enlarged figure detail. (E) Representative image of a flow cytometry histogram of anti-TUBB3 stained 
undifferentiated (white) and neuron-differentiated (green) cells. (F, G) Representative immunofluorescence microscopy images of anti-TH 
stained (F) undifferentiated and (G) neuron-differentiated SH-SY5Y cells. Inset: enlarged figure detail. (H) Representative image of a flow 
cytometry histogram of anti-TH stained undifferentiated (white) and neuron-differentiated (red) cells. (I) Graph showing the change of 
fluorescence intensity (FI) in TUBB3 and TH levels after neuronal differentiation. Dashed line (100 %) represents TUBB3 or TH mean values of 
undifferentiated cells. Bars indicate mean values and standard deviations in differentiated cells. N = 11. *: p < 0.05 (versus undifferentiated 
cells). (J) Oxygen consumption of (U) undifferentiated and (D) neuron-differentiated cells. N = 3. *: p < 0.05 (versus undifferentiated cells). (K) 
DHODH and UCK2 mRNA levels in (U) undifferentiated and (D) neuron-differentiated cells. Points represent individual samples and horizontal 
lines indicate mean ± standard deviation values. N = 4. (L–N) Representative images of western blots for (L) CAD (N = 2), (M) DHODH (N = 3) 
and (N) UCK2 (N = 2) proteins. CE, commercial enzyme; SDHA, succinate dehydrogenase subunit A. 70 μg of cell protein was used in these 
western blots (L–N). 
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occurs in differentiated cells, we measured DHODH 
and UCK2 mRNA levels in KCN-treated SH-SY5Y 
cells after their differentiation to neurons. Although 
the de novo pathway requires more ATP than the 
salvage one, DHODH mRNA expression level did not 
change, but UCK2 mRNA levels significantly 
decreased (Figure 4D). It is worth noting that a high 
percentage of OXPHOS oxygen consumption is due to 
electrons supplied to the ETC through the DHODH 
enzyme. Then, de novo pyrimidine biosynthesis is 
required not only for pyrimidine synthesis and energy 
production but also for other OXPHOS-related cell 
functions, such as the adjustment of the levels of 
signaling molecules (ATP, calcium, NAD+ and 
reactive oxygen species) to modulate different cell 
pathways [4]. This fact might explain why the de novo 
pathway is not down-regulated in neuron-
differentiated cells under low energy conditions, 
whereas the salvage pathway only involved in 




Figure 3. Leflunomide effect on neuroblastoma SH-SY5Y cells. N ≥ 3. (A) Cell proliferation (in million cells). *:  p < 0.05 versus 
untreated cells (control). (B) TUBB3 (green) and TH (red) fluorescence intensity (FI) mean and standard deviation values in neuron-
differentiated cells. Dashed line (100 %) represents TUBB3 or TH mean values of undifferentiated cells. C: untreated cells; LEF: leflunomide-
treated cells; LEF+U, leflunomide plus uridine (200 μM)-treated cells; *: p ≤ 0.0021, versus undifferentiated cells; #: p ≤ 0.0055, versus 
untreated neuron-differentiated cells. (C) Oxygen consumption in proliferating SH-SY5Y cells. *: p < 0.05, versus untreated cells. 
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Figure 4. Potassium cyanide (KCN) effect on neuroblastoma SH-SY5Y cells. N ≥ 3. (A) Oxygen consumption in proliferating SH-SY5Y 
cells at increasing KCN concentrations. *: p < 0.05, versus untreated cells. (B) Cell proliferation (in million cells) without KCN (control) and at 
10 or 25 μM KCN. (C) TUBB3 (green) and TH (red) fluorescence intensity (FI) mean and standard deviation values in neuron-differentiated 
cells. Dashed line (100 %) represents TUBB3 or TH mean values of undifferentiated cells. *: p < 0.05, versus undifferentiated cells. Horizontal 
red lines indicate p values ≤ 0.0004 between control untreated neuron-differentiated cells (C), KCN-treated neuron-differentiated cells (KCN) 
and KCN plus uridine-treated neuron-differentiated cells (KCN+U), as indicated. (D) DHODH (pink) and UCK2 (purple) mRNA mean and 
standard deviation values in C, KCN and KCN+U neuron-differentiated cells. Dashed line (100 %) represents DHODH and UCK2 mRNA mean 
values of undifferentiated cells. Black horizontal lines indicate p values < 0.05 between groups as indicated. 
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Uridine recovers neuronal differentiation of OXPHOS 
dysfunctional cells 
It was previously reported that uridine protected AD 
fibroblasts and normal human neuronal progenitor cells 
against azide toxicity [26, 27], another CIV inhibitor. 
Supplementation of uridine to aged rats increased brain 
neurofilament levels [28]. Besides, a uridine effect on 
neuronal differentiation was reported. Thus, in rat PC12 
pheochromocytoma cells and mouse N2a and human 
LAN-5 and SH-SY5Y neuroblastoma cells, exogenous 
uridine enhanced cell differentiation as evidenced by 
increased number of neurite-bearing cells, neurites per 
cell, neurite branching, neurite length, and neurite 
neurofilament levels [27, 29–31].  
 
We observed that uridine 200 μM was able to restore 
UCK2 mRNA levels in KCN-treated neuroblastoma SH-
SY5Y cells (Figure 4D). Perhaps an excess of the UCK2 
substrate uridine acts as a positive regulator for the 
expression of UCK2 mRNA. Uridine completely 
recovered TUBB3 and TH protein levels in these cells 
(Figure 4C). Uridine increases the synthesis of UDP-N-
Acetylglucosamine (UDP-GlcNAc) [32]. This compound 
transfers GlcNAc to different proteins, such as 
transcription factors or histones, which implicates this 
modification in transcriptional regulation [33, 34]. Maybe, 
this is the way uridine recovers TUBB3 and TH 
expression. 
 
All these results indicate that OXPHOS dysfunction 
affects de novo pyrimidine nucleotide biosynthesis 
pathway and has negative consequences on neurons 
generated from neuroblastoma SH-SY5Y cells. As 
previously commented upon, it is considered that the 
activity of the de novo pathway is low in fully 
differentiated cells, such as mature brain neurons [5], 
but the cell’s capacity to salvage uridine is limited, and 
no cell can tolerate complete DHODH inhibition [35]. 
Moreover, some observations suggest that de novo 
pyrimidine biosynthesis pathway is also important in 
mature neurons from adult human brain [36]. 
 
The de novo pyrimidine biosynthesis pathway is 
present in adult human brain 
 
DHODH mRNA 
According to RNA-Seq studies reported in the 
Expression Atlas webpage (https://www.ebi.ac.uk/gxa/ 
home; accessed April 23, 2018), CAD, DHODH, and 
UMPS mRNAs are found in brain of primates, rodents, 
other placental and marsupial mammals, birds, and 
amphibians (Supplementary Table 1). There are no large 
differences in the number of transcripts per million for 
genes from the de novo pyrimidine biosynthesis pathway 
among species. By comparison, UCK2 mRNA levels, 
from the pyrimidine salvage pathway, are also very much 
alike. The presence of these mRNAs in adult rat brain 
was confirmed by in situ hybridization analysis [37]. 
Neocortex, cerebellar cortex, and hippocampus, which 
have high neuronal densities, showed high signal 
intensities. 
 
Since CAD, DHODH, and UMPS mRNAs are found in 
brain from different species, expression of these genes 
may also be in the human brain. We tuned up a RT-
qPCR to quantify DHODH, normalized by GAPDH, 
mRNA levels in four different regions of adult human 
brain from clinical and histopathological controls 
(CHPC) (Supplementary Table 2 and Figure 5A). We 
also determined UCK2 mRNA levels (Supplementary 
Table 2 and Figure 5B). Depending on the brain region, 
the DHODH mRNA amount was 4.3 - 9.7 times lower 
than that of UCK2 mRNA. DHODH and UCK2 mRNA 
levels in the locus ceruleus (LC) were significantly 
higher than those from the other brain regions. Dentate 
gyrus (DG) UCK2 mRNA levels were also significantly 
different from those of other brain regions (Figure 5A, 
5B). A review of the Expression Atlas Webpage 
(accessed April 23, 2018) showed that DHODH and 
UCK2, but also CAD and UMPS, mRNAs were found 
in different regions of adult human brain 
(Supplementary Table 3). Similar mRNA levels were 
found for different genes, in different brain regions, and 
in various studies. 
 
DHODH protein 
By using a non-commercial anti-DHODH polyclonal 
antibody, the immunoblotting of protein from adult rat 
brain revealed the presence of DHODH in different 
regions, such as cortex, hippocampus, striatum, 
cerebellum, brain stem, and spinal cord [38]. 
 
To confirm the occurrence of enzymes from the de novo 
pyrimidine biosynthesis pathway in adult human brain, 
we first performed a western blot for CAD. The anti-
CAD monoclonal antibody showed a unique band of the 
expected size (Figure 6A). However, the anti-DHODH 
polyclonal antibody showed multiple bands (Figure 
6B). One of them was located in the expected position 
for a protein which size is the same of DHODH (43 
kDa). Additionally, this signal coincided with the band 
for a commercial DHODH lacking its first 31 amino 
acids (ab128451, Abcam, Cambridge, UK), with 
approximately 40 kDa expected size. The analysis of 
different brain regions, such as hippocampus, entorhinal 
cortex (EC), and putamen suggested the presence of 
DHODH in all of them, but again, multiple bands were 
observed (Figure 6C). An anti-DHODH monoclonal 
antibody resulted in a cleaner lane, but still with several 
bands (Figure 6D). One of them was located in the 
expected position, coinciding with the site for the 
commercial DHODH. To produce this monoclonal 
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antibody, a DHODH fragment (amino acid positions 32 
-141) was used (ab54621, Abcam, Cambridge, UK). 
This antibody also recognized the same DHODH 
fragment generated by us (Figure 6E).  
 
In an attempt to further confirm the presence of this 
protein in adult human brain, we carried out proteomic 
analyses of the western blot candidate band. In parallel 
to the brain sample, we also loaded a sample from 
neuroblastoma SH-SY5Y cell line, because proliferating 
cells require a large amount of pyrimidine and are 
dependent on DHODH, as we have previously shown 
(Figure 6F). Peptide mass fingerprinting did not show 
the protein in these samples. However, a parallel 
reaction monitoring (PRM) proteomics analysis showed 
3 DHODH peptides in the western blot band 
corresponding to neuroblastoma SH-SY5Y cell 
homogenate (Supplementary Figures 2A and 3), but 
DHODH could not be confirmed in the band 
corresponding to brain homogenate, probably due to a 
high background. Peptide mass fingerprinting and PRM 
proteomics analyses suggested, but did not confirm, the 
presence of DHODH in one of 6 spots from a two-
dimensional electrophoresis gel (Supplementary Figures 
2B and 4). It may be that the brain DHODH quantity 
was too low. However, a western blot of a brain sample 
using two different concentrations of a commercial 
DHODH allowed us to estimate its brain concentration 
as close to 2.2 ng DHODH/mg brain (Figure 6G). By 
ELISA, a mean concentration of 128.3 pg DHODH/mg 
brain was estimated in hippocampus from five control 
individuals. Surprisingly, the UCK2 mean concentration 
was much lower, 0.6 pg UCK2/mg brain. These results 
are in line with those SH-SY5Y cells, in which higher 
UCK2 mRNA levels but much lower UCK2 protein 




Figure 5. Expression of genes encoding (A) DHODH and (B) UCK2 proteins from both pyrimidine nucleotide synthesis pathways. GAPDH mRNA 
levels have been used to normalize. CA1: hippocampal cornus ammon 1; EC: entorhinal cortex; DG: dentate gyrus; LC: locus ceruleus. Points 
represent individual samples and horizontal lines indicate mean ± standard deviation values. P values for Kruskal-Wallis tests are indicated under 
the graphs. Horizontal red lines indicate between-regions p values (p < 0.0083) fulfilling the post-hoc Bonferroni/Dunn criteria.  
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DHODH activity 
DHODH histochemistry analysis in adult rat brain 
showed high staining in different regions, with the 
hippocampus presenting a characteristic pattern [38]. 
We could not get optimally-cryopreserved adult 
human brain samples appropriate for histochemical 
studies. However, we detected high DHODH activity 
in adult mouse brain homogenate and Brequinar, a 
DHODH inhibitor, largely reduced the staining (Figure 
7A–7C). Moreover, fresh samples from adult mouse 
brain consume significantly more oxygen when 
dihydroorotate was used as electron donor (Figure 
7D). Leflunomide reduces oxygen consumption 
(Figure 7E). Similar to proliferating SH-SY5Y cells, in 
the absence of dihydroorotate, leflunomide was able to 
reduce oxygen consumption to a residual 60 %. This 
result highlights the importance of de novo pyrimidine 
biosynthesis pathway in adult brain, not only for 
pyrimidine production, but also for OXPHOS function. 
 
Supporting our results on adult brain DHODH activity, 
in the 1960s and 1970s, different publications showed 
the presence of the de novo pyrimidine biosynthesis 
pathway in adult mouse, rat, and cat brain. Thus, the 
intracranial injection of radioactive intermediates for 
this pathway resulted in an early appearance of 
radioactive pyrimidine nucleotides in the brain [39–41]. 
Moreover, administration of these radioactive 
compounds to adult rat brain sections or homogenates 
also produced radioactive pyrimidine nucleotides [40, 
42–48]. Finally, high DHODH activity was found in 
adult rat brain homogenate [49]. 
 
DHODH immunohistochemistry 
Previous results strongly suggested the presence of the 
de novo pyrimidine biosynthesis pathway in adult 
human brain. However, these results did not indicate in 
which cell type this route was expressed. 
Immunocytochemical staining with anti-DHODH 
antibody confirmed DHODH in frontal cortex, 
hippocampus, striatum, and substantia nigra pars 
reticulate in the adult rat brain. Immunoreactivity was 
found in neuronal bodies and absent in neuroglia [38]. 
Moreover, neuronal incorporation of radioactive orotic 
acid intraventricularly injected into adult rat brain was 




Figure 6. Western blot detection of selected proteins from the de novo pyrimidine biosynthesis pathway in adult human 
brain. (A) CAD protein in 40 and 80 μg of brain sample, B1 and B2, respectively. (B) DHODH protein in 180 μg of brain (B) protein using 
polyclonal antibody. Lane E: commercial DHODH enzyme lacking its 31 first amino acids (250 ng of protein). (C) DHODH protein in 
hippocampus (H, 100 μg of protein), entorhinal cortex (EC, 180 μg of protein) and putamen (P, 180 μg of protein) using polyclonal antibody. 
White arrows indicate the corresponding band for DHODH. (D) DHODH protein using monoclonal antibody for detection of commercial 
enzyme lacking its first 31 amino acids (E, 250 ng of protein) and in 40 and 80 μg of brain sample, B1 and B2, respectively. (E) Fragment of 
DHODH protein used as immunogen to produce the monoclonal antibody. NT and T homogenates of untransformed bacteria and bacteria 
transformed with the DHODH fragment sequence, respectively. S and P: supernatant and pellet, respectively. (F) DHODH protein in 
neuroblastoma SH-SY5Y cell line (70 μg of protein) and brain tissue (B, 250 μg of protein) using polyclonal antibody. (G) Quantification of 
brain DHODH protein with the polyclonal antibody in brain (B, 180 μg of protein) by comparison with the commercial enzyme lacking its first 
31 amino acids at 0.4 and 4.0 ng (E1 and E2), respectively. M: molecular weight marker. 
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Immunohistochemistry staining of adult human samples 
with anti-CAD and anti-DHODH antibodies confirmed 
the presence of both enzymes in different brain regions, 
such as amygdala, cerebellum, DG, EC, frontal cortex, 
putamen, and striatum (Figure 8). Stronger staining was 
observed in zones with high neuronal density whereas 
the immunoreactivity was hardly seen in white matter. 
Furthermore, no marking is noted in cytoplasm of glial 
cells (Figure 8). In neurons, staining is located in 
perikarya and dendrites (Figure 8 and Supplementary 
Figure 5). Supporting our results, the Human Protein 
Atlas Webpage (https://www.proteinatlas.org/, accessed 
April 26, 2018) shows that CAD and DHODH proteins 
appear, at low levels, in different adult brain regions, 
such as cerebral cortex, hippocampus, caudate, and 
cerebellum. Neurons and glial cells showed medium-
low and low or no staining, respectively. 
 
Although CAD is a cytosolic enzyme and DHODH is a 
mitochondrial one, the pattern of staining is very similar 
for both of them. These enzymes together with UMPS, 
another cytosolic enzyme, belong to the same metabolic 
pathway, and it has been shown that CAD and UMPS 
are placed around and outside mitochondria, closely 
associated with their outer membranes [5, 51]. Then, the 
enzymes for the complete biosynthetic pathway are 
physically associated in the cell. 
 
All these results confirm the presence of the de novo 
pyrimidine biosynthesis in mature neurons from adult 
human brain. We wondered if this biochemical pathway 
would be affected in Alzheimer disease patients. 
 
Pathways for pyrimidine nucleotide synthesis are 
altered in brains from Alzheimer disease patients 
 
UCK2 and DHODH mRNA levels in different 
Alzheimer disease stages 
To study the biochemical pathways for pyrimidine 
nucleotide synthesis in AD patients, we analyzed UCK2 
and DHODH mRNA levels from different brain 
regions, such as LC, EC, hippocampal cornus ammon 1 
(CA1), and DG. Neurofibrillary pathology is found in 
LC and EC in AD Braak and Braak stages I/II, CA1 in 
AD stages III/IV, but not in DG, even in AD stages 
V/VI [52].  
 
AD stages were significantly associated with UCK2 
mRNA levels in all these brain areas (Figure 9A–9D). 




Figure 7. DHODH activity. (A–C) Histochemical detection of DHODH activity in adult mouse brain. (A) Negative control, no dihydroorotate 
(DHO) added. (B) DHODH activity, DHO added. (C) DHODH activity inhibition, DHO and its inhibitor Brequinar (20 μM) added. (D) Oxygen 
consumption increment in adult mouse brain after addition of DHO; horizontal black line indicates significant difference. (E) Inhibition of 
oxygen consumption by leflunomide in brain homogenate with (green) and without (blue) addition of DHO. Dashed line (100 %) indicates 
mean values of oxygen consumption in uninhibited cells. Bars indicate oxygen consumption in leflunomide inhibited cells N = 3. *: p < 0.05 
(versus uninhibited cells). 
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higher levels were found in more severe AD stages, than 
in the other regions, where UCK2 mRNAs tended to 
decrease as neuropathology progressed. A potential 
explanation, already pointed out to justify lower CA1 
mitochondrial DNA (mtDNA) deletion levels [53], 
would be that a selective and progressive apoptosis of 
CA1 neurons with decreasing UCK2 mRNA levels may 
shift the pattern towards an apparent increase of ‘healthy’ 
cells. In contrast, DHODH mRNA levels were not 
associated with AD stages (Figure 9E–9H). These results 
resemble those previously found in KCN-treated SH-
SY5Y cells, in which energy stress provoked a decrease 
in UCK2 mRNA levels but did not modify DHODH 
mRNA levels (Figure 4D), and the same explanation 
might be advanced. Despite this, and except for LC, 
positive correlations between DHODH and UCK2 
mRNA levels were observed in these regions (Figure 9I–
9L), thus suggesting that both pathways are essential.  
Associations between these mRNA levels and AD 
stages are not due to unbalanced sex or postmortem 
delay distributions. No association was found between 
AD stages and RNA integrity number (RIN) values. AD 
stages and age are significantly associated [54]. 
Although there were no significant correlations between 
age and DHODH mRNA levels, age and UCK2 mRNA 
levels were significantly correlated (Supplementary 
Figure 6A–6H). These correlations were negative in 
LC, EC, and DG, and positive for CA1. To evaluate the 
relevance of AD stages versus age on UCK2 mRNA 
levels, we divided individuals according to their UCK2 
mRNA levels (higher and lower half) for each brain 
region and AD stage, and compared their ages 
(Supplementary Figure 6I–6L). Except for DG AD I/II 
stages, there were no significant differences. This result 
suggests that variation in UCK2 mRNA levels is more 




Figure 8. Immunohistochemical detection of neuronal CAD (A–F) and DHODH (G–L) in adult non-AD human brain. (A, G) Negative control. 
No primary antibody. (B, H) Positive control. (C, I) Dentate gyrus. (D, J) Granular layer of dentate gyrus. (E, K) Frontal cortex. (F, L) Entorhinal 
cortex. Scale bar in L represents 1000 μm in C and I; 100 μm in A, B, D, E, G, H, J and K; and 20 μm in F and L. 
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If lower UCK2 mRNA levels in different brain regions 
correspond with a decrease in pyrimidine synthesis 
pathway, and, as it has been recently reported, AD 
subjects show lower uridine concentrations in plasma and 
cerebrospinal fluid [55–59], then AD patients probably 
have a cerebral deficiency in many cellular functions 
related to the metabolism of uridine. Therefore, it can be 
suggested that uridine therapeutic administration would 
improve biochemical pathways related to brain function. 
In this line, uridine treatment attenuates the impairments 
in learning and memory observed in gerbil, stressed rat, 
and AD mouse models [27, 60–63]. Nutrient 
combinations including uridine supplementation have 




Figure 9. mRNA levels of selected genes encoding proteins from both pyrimidine nucleotide synthesis pathways. Graphs 
represent mean ± standard deviation values of UCK2 (A–D), DHODH (E–H), and DHODH - UCK2 correlations (I–L); respectively. GAPDH mRNA 
levels have been used to normalize. CA1: hippocampal cornus ammon 1; EC: entorhinal cortex; DG: dentate gyrus; LC: locus ceruleus. Each 
point represents an individual sample. The p values for Kruskal-Wallis or ANOVA tests are indicated under the graphs. Red and black 
horizontal lines indicate significant p values, fulfilling (p < 0.0083, p < 0.0167 in LC) or no (p ≤ 0.05) the post-hoc Bonferroni/Dunn criteria. 
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As previously proposed, reduction in UCK2 mRNA 
levels might be secondary to a drop in energy 
production. OXPHOS is the main energy provider to 
power neuronal activity [70]. Thus, OXPHOS 
dysfunction in AD patients might explain the brain 
reduction in UCK2 mRNA levels. 
 
Reduction in MT-CO1 and COX4I1 mRNA levels is 
associated with an increase in DHODH/UCK2 ratio in 
entorhinal cortex from Alzheimer disease patients 
We used mtDNA-encoded MT-CO1 and nuclear DNA 
(nDNA)-encoded COX4I1 mRNA levels as surrogates 
of OXPHOS function. A comparison of mRNA levels 
and AD stages in different brain regions showed a 
significant association in EC (Figure 10A, 10B). In this 
region, AD stages V/VI patients had lower MT-CO1 
and COX4I1 mRNA values than controls. The COX4I1 
mRNA levels were also associated to AD stages in DG 
and LC. We noted above that AD stages and age are 
significantly associated. Moreover, it was previously 
reported that MT-CO1 mRNA levels were significantly 
lower in cerebral hemispheres from 28 than 9 months 
old rats [71]; and the mRNA levels for the three 
mtDNA-encoded CIV subunits were lower in cerebral 
cortex from 24- than 18-month-old mice [72]. We have 
also observed a negative significant correlation between 
MT-CO1 and COX4I1 mRNA levels and age, but only 
in EC (Figure 10C, 10D). To evaluate the importance of 
AD stages versus age on EC MT-CO1 and COX4I1 
mRNA levels, we divided individuals according to their 
MT-CO1 and COX4I1 mRNA levels (higher and lower 
half) for each AD stage, and compared their ages 
(Figure 10E, 10F). Except for EC AD V/VI stages, there 




Figure 10. Entorhinal cortex MT-CO1 and COX4I1 mRNA levels. (A, B) MT-CO1 and COX4I1 mRNA levels, normalized by 18S rRNA, in 
different AD stages. Points represent individual samples and horizontal lines indicate mean ± standard deviation values. The p value for 
Kruskal-Wallis test is indicated under the graph. Red line indicates p < 0.0083 (fulfilling the post-hoc Bonferroni/Dunn criteria). (C, D) 
Correlations between age and MT-CO1 or COX4I1 mRNA levels. (E, F) Age distribution, according to MT-CO1 or COX4I1 mRNA levels, in 
different AD stages. Green and red dots indicate higher and lower half MT-CO1 or COX4I1 mRNA levels, respectively. Blue arrow indicates 
significant differences, in age, between individuals with higher and lower MT-CO1 mRNA levels. (G, H) Correlations between MT-CO1 or 
COX4I1 mRNA levels and DHODH/UCK2 ratio. (I) DHODH/UCK2 ratio in different AD stages. Points represent individual samples and horizontal 
lines indicate mean ± standard deviation values. The p value for Kruskal-Wallis test is indicated under the graph. Black and red lines indicate p 
≤ 0.05 or, fulfilling the Bonferroni/Dunn criteria, p < 0.0083.  
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what would be expected, and what is observed in the 
correlation, the youngest individuals had lower MT-
CO1 mRNA levels. This result suggests that variation in 
MT-CO1 and COX4I1 mRNA levels is more dependent 
on AD stage than on age. 
 
A decrease in mRNA levels for mtDNA-encoded CIV 
subunits has also previously been described in some 
brain regions of AD patients [73–82]. Furthermore, low 
mRNA levels from nDNA-encoded CIV genes were 
informed in AD patients [82–86]. This reduction in 
mRNA levels for CIV subunits is probably responsible 
for the widely reported brain CIV deficit in many AD 
patients [75, 87–108].  
 
Interestingly, in EC, MT-CO1 and COX4I1 mRNA 
levels negatively correlate with DHODH/UCK2 ratio 
(Figure 10G, 10H). In EC, this ratio was associated with 
AD stages (Figure 10I), and was significantly higher in 
AD stages V/VI than that in I/II and III/IV. The ratio 
did not correlate with age. The higher DHODH/UCK2 
ratio in EC of AD stages V/VI is perhaps an attempt to 
compensate for a reduction in energy production by a 
CIV defect. As down-regulation of the de novo pathway 
might affect many vital reactions, because of its 
importance for OXPHOS function, a reduction in the 
salvage pathway, to avoid dispensable ATP 
consumption, would cause a higher DHODH/UCK2 
ratio. 
 
As a conclusion, our results confirm that an OXPHOS 
dysfunction, throughout an altered de novo pyrimidine 
biosynthesis pathway, can affect variables of post-
mitotic cells, such as neuronal differentiation; that the 
de novo pyrimidine biosynthesis pathway is present in 
adult human brain; and that both de novo and salvage 
pyrimidine nucleotide synthesis pathways appear to 
be unbalanced in AD brain. However, more work is 
required to link these pathways for pyrimidine 
nucleotide synthesis to an OXPHOS defect in AD 
brain. In particular, the determination of pyrimidine 
nucleotide levels and DHODH and UCK2 activities in 





Cells, culture conditions, and differentiation 
 
The human neuroblastoma SH-SY5Y cell line was 
obtained from Sigma-Aldrich (catalogue number 
94030304, lot 13C014, P 17; St. Louis, MO, USA). 
These cells were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) containing 25 mM glucose,  
4 mM L-glutamine, and 1 mM sodium pyruvate, 
supplemented with 10 % fetal bovine serum (FBS). 
Differentiation was induced following optimized 
protocols [109], but instead of 25 mM glucose, we used 
5 mM galactose media to enhance OXPHOS function. 
Cells were maintained at 37 °C in a humidified 
atmosphere of 5 % CO2. 
 
Three growth curves were performed for each 
condition, and each time point (from day 0 to day 12) 
was counted in triplicate.  
 
Human and mouse brains 
 
Brain samples from three healthy adult individuals were 
obtained from the Institute of Neuropathology HUB-
ICO-IDIBELL Biobank following the guidelines of 
Spanish legislation on this matter and the approval of 
the local ethics committee.  
 
Mouse brain was obtained from C57BL/6J adult 
individuals (2 to 8 months) after the approval of the 
local ethics committee. Animals were killed by 
decapitation and the brain was immediately removed. 
For histochemistry analysis, brains were covered with 
optimal cutting temperature (OCT) compound and 
frozen at - 80 °C. For oxygen consumption studies, 




Brain RNA samples were obtained from the Institute of 
Neuropathology HUB-ICO-IDIBELL Biobank. The 
post-mortem interval between death and tissue 
processing was between 2 and 22 h 15 min. Processing 
of brain tissue has been detailed elsewhere [110]. 
Neuropathological diagnosis and staging of AD were 
based on the classification of Braak [52]. CHPC were 
middle-aged individuals (n = 20, 11 men, 9 women; 
age, 50.7 ± 7.2 years) with no neurological or mental 
disorders and without lesions on the neuropathological 
study. Four brain regions were examined: CA1, DG, 
EC, and LC. A summary of all analyzed individuals is 
provided (Supplementary Table 2). Not all regions were 
assessed in every case because of the limited 
availability of tissues. 
 
RNA purification 
RNA from frozen cells and tissue was extracted 
following the instructions of the supplier (NucleoSpin 
RNAII, Macherey-Nagelsupplier, Düren, Germany and 
RNeasy Mini Kit, Qiagen, Hilden, Germany). RIN and 
28S/18S ratios were determined with the Agilent 
Bioanalyzer (Agilent Technologies, Inc., Santa Clara, 
CA). Samples were digested with DNase, and RNA 
concentration was evaluated using NanoDrop 
Spectrophotometer (Thermo Fisher Scientific, Waltham, 
MA).  
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qPCR 
The mRNA levels were measured with the RT-qPCR 
method using an Applied Biosystems StepOneTM Real-
Time PCR System Thermal Cycling Block and a ViiA 7 
Real-Time PCR system. DHODH, UCK2 and MT-CO1 
mRNA levels were determined in triplicate with RT-
qPCR using TaqPathTM 1-Step Multiplex Master Mix 
(DHODH and UCK2) and TaqMan® RNA-to-CTTM 1-
Step Kit (MT-CO1). The expression levels were 
normalized using GAPDH mRNA or 18S rRNA. Serial 
dilutions of recombinant plasmid DNA were included in 
each experiment to generate a standard curve for 
DHODH, UCK2, and GAPDH. 
 
Western blot and ELISA 
 
For immunoblot analysis, protein levels were analyzed 
in whole-cell lysates obtained using cell lysis buffer 
(RIPA) or in tissue homogenates obtained using glass 
potters at 500 rpm, with 10 strokes, and Tris-buffered 
saline (TBS). Samples were resolved on SDS-PAGE 
minigels (Miniprotean, Bio-Rad, Hercules, CA, USA) 
and were transferred to PVDF membranes (Trans-Blot® 
Turbo™ Mini PVDF Transfer Pack, Bio-Rad) using a 
Trans-Blot® TurboTM Blotting System (Bio-Rad). 
Membranes were analyzed by immunoblotting with the 
following antibodies: rabbit polyclonal anti-DHODH 
(1:500) from biorbyt (orb247660, Cambridge, UK), 
rabbit mono and polyclonal anti-CAD (1:500), mouse 
monoclonal anti-DHODH (1:1,000), mouse polyclonal 
anti-UCK2 (1:250) from Abcam (ab40800, ab99312, 
ab54621, ab167683, Cambridge, UK), mouse anti-actin 
(1:1,000) from Sigma (A5441, St. Louis, MO, USA), 
and rabbit anti-CII (1:1,000) from Thermo Fisher 
Scientific (459200, Waltham, MA, USA). After 
washing, the membrane was incubated with peroxidase-
conjugated secondary antibodies (1:5,000 or 1:10,000) 
from Thermo Fisher Scientific for 1 h at room 
temperature or it was incubated with appropriate 
secondary antibodies DyLight™ (SA535521, 
SA535571, 35568, 35518, Thermo Fisher Scientific). 
Bands were visualized with Super Signal West Pico 
Chemiluminescence Substrate from PIERCE® (Thermo 
Fisher Scientific) or using Odyssey® CLx Imaging 
System (LI-COR Biosciences, San Jose, CA, USA). 
 
The DHODH peptide corresponding to amino acids 32–
141 was heterologously expressed in Escherichia coli 
strain C41 (DE3) as a recombinant peptide using 
pET28a expression vector.  
 
The quantitative determination of DHODH and UCK2 
proteins was performed using commercially available 
Human Dihydroorotate Dehydrogenase (DHODH) 
ELISA kit and Human Uridine-Cytidine Kinase 2 
(UCK2) ELISA kit (Abbexa, Cambridge, UK). Protein 
extracts concentrations were measured by Bradford 
assay. Samples were collected and DHODH and UCK2 
levels were immediately measured, following the 
manufacturer’s instructions.  
 
Histochemistry and immunohistochemistry 
 
Immunocytochemistry 
Cells were fixed with 4 % paraformaldehyde for 15 min 
at room temperature and permeabilized using 0.1 % 
Triton X-100 (Sigma-Aldrich) diluted in PBS for 10 
min. To block unspecific epitopes, cells were incubated 
with 0.1 % bovine serum albumin. Primary antibodies 
(rabbit anti-TUBB3, 1:1,000, from Abcam and rabbit 
anti-TH, 1:200, from Sigma-Aldrich) were incubated 
overnight at 4 °C followed by incubation with 
appropriate fluorescently labeled secondary antibodies, 
Alexa Fluor® 488 and 594 (Molecular Probes, Eugene, 
Oregon, USA) for 1 h at room temperature. Finally, cell 
nuclei were counterstained with 4',6-diamidino-2-
phenylindole (DAPI) (Sigma-Aldrich). 
 
Histochemistry 
DHODH histochemistry was performed using the 
nitroblue tetrazolium/formazan technique on 20 µm 
cryostat sections of adult mouse brain. The oxidation of 
its substrate dihydroorotate (DHO) (10 mM) can be 
determined by trapping the electrons with tetrazolium (1 
mM) in the presence of cyanide (10 mM), to prevent 
their further flow along the chain to oxygen, in 
phosphate buffer pH 8, 37 °C, 60 min. The insoluble 




This protocol was performed at the Anatomic Pathology 
Core Unit of the Health Sciences Institute of Aragon 
(Zaragoza, Spain). Once paraffin blocks were made, 2.5 
µm sections were cut with a rotation microtome (Leica 
RM2255) and paraffin sections were taken on superfrost 
glass slides. Slides were air dried at 37 °C overnight 
and, for immunohistochemistry stain, they were 
deparaffinized in xylene for 10 min, rehydrated in a 
grades series of ethanol (100, 100, 96, 70, 5 min each) 
and distilled water for 5 min. After rehydration, antigen 
retrieval was performed by means of the PT Link 
(Dako) at 95 °C for 20 min in a low/high pH buffer 
(Dako antigen retrieval, low/high pH). After retrieval, 
automated immunostaining was performed with a 
previously optimized protocol. For this process 
endogenous peroxidase was first blocked (EnVision 
FLEX Peroxidase-Blocking) followed by 5 min 2 
washing steps (Dako wash buffer); mouse monoclonal 
anti-DHODH 1/50 and rabbit polyclonal anti-CAD 
1/200 (ab54621, ab99312, Abcam, Cambridge, UK) 
primary antibodies were used with 40 min incubation 
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time. After 2 wash steps a dual rabbit/mouse HRP 
conjugated visualization system for signal amplification 
was used (Envision Flex HRP, Dako). After 3 wash 
steps (Dako wash buffer, 5 min each), 3,3'-
Diaminobenzidine (DAB) was used for signal 
development after precipitation at primary antibody 
binding sites. 
 
The double staining of CAD, DHODH and UCK2 with 
NeuN and GFAP, was performed using commercially 
available PolyStain TS kit (NB-23-00131, Neo-Biotech, 
Nanterre, France). Anti-CAD, anti-DHODH and anti-
UCK2 antibodies (ab99312, ab232767, ab60222, from 
Abcam) were incubated overnight at 4 °C at 1/50. Anti-
NeuN (ab104224, Abcam) and anti-GFAP (G3893, 




Cell suspensions were first fixed with 4 % 
paraformaldehyde for 15 min at 4 °C and permeabilized 
using a commercial buffer (Thermo Fisher Scientific). 
Samples were incubated overnight with the primary 
antibodies rabbit anti-TUBB3 (1:1,000) from Abcam 
and rabbit anti-TH (1:200) from Sigma, and then 
washed with PBS (Thermo Fisher Scientific). Cells 
were incubated for 1 h with appropriate secondary 
antibodies Alexa 488 (Thermo Fisher Scientific), 
washed, and then analyzed on a BD FACScan System 
(Becton-Dickinson, San Jose, CA, USA). 10,000 cells 





Neuroblastoma SH-SY5Y cell line: Cells were cultured 
in 5 mM galactose media. The cells were then collected 
by trypsinization, washed, counted, and resuspended at 
1.5 x 106 cells/ml. Endogenous and inhibited respiration 
(with leflunomide or cyanide) analyses were performed. 
Each condition was analyzed three times.  
 
Mouse brain 
Brain was immediately obtained after animal death, 
dissected on ice, and weighed on an analytical balance. 
The dissected brain was directly transferred into ice-cold 
mitochondrial respiration medium (MIR05: 110 mM 
sucrose, 60 mM K+-lactobionate, 0,5 mM EGTA, 3 mM 
MgCl2, 20 mM taurine, 10 mM KH2PO4, 20 mM HEPES 
and 1 g/l BSA, pH 7.1). Tissues were homogenized in the 
same medium with a pre-cooled glass potter at 1,000 
rpm, 16 strokes. Resulting homogenates containing 10 
mg tissue wet weight were suspended in 1 ml of ice-cold 
MIR05. To measure the oxygen consumption in the 
presence of the substrate, MIR05 medium contained 6 
mM of DHO. Endogenous and inhibited respiration (with 
leflunomide) analyses were performed. Each condition 
was analyzed three times. 
 
Oxygen consumption of cells and mouse brain was 
analyzed using the high-resolution oxygraph 
OROBOROS®.  
 
Mass spectrometry analysis of protein spots  
 
Protein identification by peptide mass fingerprint 
Spots were excised from gels, reduced, alkylated and 
digested with trypsin sequencing grade (Roche 
Molecular Biochemicals) [111]. Produced peptides were 
analyzed in a 4800 Plus Proteomics Analyzer MALDI-
TOF/TOF mass spectrometer (Applied Biosystems, 
MDS Sciex, Toronto, Canada) at the Proteomics Unit of 
Complutense University of Madrid. The MS data was 
searched against SwissProt Data Base with taxonomy 
restriction to human (553,231 sequences) using 
MASCOT 2.3 (http://www.matrixscience.com) search 
engine through Global Protein Server v 3.6 software 
(ABSciex). The search parameters were 
carbamidomethyl cysteine as fixed modification and 
oxidized methionine as variable modification. Peptide 
mass tolerance was 50 ppm and up to 1 missed trypsin 
cleavage site allowed. All identified protein 
outperformed the probability scores fixed by mascot as 
significant with a p-value minor than 0.05. 
 
Protein identification by PRM 
Desalted peptides from digested protein were analyzed 
by targeted proteomics to identify only the protein of 
interest in this study (PYRD or DHODH). The software 
Skyline 4.1 was used to build and optimize the PRM 
method for detection of unique peptides from DHODH 
[112]. An inclusion list consisted of m/z of resultant 
target candidates for each peptide was exported to 
Xcalibur 4.0 (Thermo Scientific) acquisition software of 
Q-Exactive HF mass spectrometer. The final PRM 
methods included one protein, 49 peptides and 112 
precursors. The peptides for PRM were analyzed by 
nanoflow liquid chromatography-tandem mass 
spectrometry in an EASY-nLC 1000 System coupled to 
the Q-Exactive HF mass spectrometer through the 
Nano-Easy spray source (all from Thermo Scientific, 
Bremen, Germany). MS Data acquisition was 
performed in Q-Exactive HF using PRM method. Then 
Data were analyzed in Skyline software and identified 
with Mascot search engine thorough Proteome 
discoverer 2.2 software (Thermo Scientific). Peptides 
identifications based on MSMS data were used by 
skyline to generate a spectral library. To confirm 
DHODH detection, data were processed against the 
PRM-library on Skyline and manually inspected to 
ensure consistency between the transitions detected 
and the sequences of peptide searched. 
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Statistical analysis 
 
The statistical package StatView 6.0 and GraphPad 
Prism 5.0 were used to perform all the statistical 
analyses. The normality of distribution was analyzed 
with Kolmogorov-Smirnov test. Mann-Whitney or 
Kruskal-Wallis non-parametric tests were used when 
values did not follow a normal distribution, while the 
ANOVA test was used for normal variables. To 
compare more than two groups post-hoc tests were also 
performed. All data were expressed as mean ± standard 
deviation and significance levels were set at p < 0.05 
and the levels indicated by the post-hoc tests. Statistical 
values in cell lines were obtained after three or more 
independent experiments. In each independent 
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Supplementary Figure 1. Effect of uridine (U) on oxygen consumption of leflunomide (LEF)-untreated and treated SH-SY5Y 
cells. Dashed line (100 %) represents mean values of untreated cells. Bars indicate main values and standard deviations of U, LEF and LEF+U 




Supplementary Figure 2. Results of the parallel reaction monitoring proteomic analysis. MS/MS spectrum of the FTSLGLLPR 
peptide. (A) Neuroblastoma SH-SY5YH cell line homogenate from the candidate western blot band. (B) Adult human brain homogenate 
from the candidate 2D-western blot spot. 
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Supplementary Figure 3. Results of the parallel reaction monitoring proteomic analysis for the candidate western blot band 
from the neuroblastoma SH-SY5YH cell line homogenate. MS/MS spectra of the TSVDAAEDYAEGVR (A, B) and VPIIGVGGVSSGQDALEK 




Supplemental Figure 4. 2D-western blot analysis of the adult human brain. (A) SDS-PAGE 10 % results. (B) PVDF membrane 
showing the selected spots for peptide mass fingerprinting (blue and red arrows) and parallel reaction monitoring (PRM) (red arrow) 
proteomics analyses. 
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Supplementary Figure 5. Neuronal location of enzymes for de novo pyrimidine biosynthesis (CAD and DHODH) and salvage 
(UCK2) pathways. Representative immunohistochemical images of CAD (A, D), DHODH (B, E) and UCK2 (C, F) in frontal cortex of human 
brain, where neuronal cytoplasms are stained brown. The neuronal nucleus (NeuN, blue stain, A–C) and astrocyte cytosol (GFAP, blue stain, 
D–F) markers are also indicated. (63 x). 
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Supplementary Figure 6. mRNA expression by age and AD stages. Correlation between DHODH (A–D) or UCK2 (E–H) mRNA levels 
with age. GAPDH mRNA levels have been used to normalize. Correlation coefficients and p values are shown in the graphs. (I–L) Age 
distribution, according to UCK2 mRNA levels, in different AD stages. Green and red dots indicate higher and lower half UCK2 mRNA levels, 
respectively. Blue arrow in panel K indicates separation by age between individuals with higher and lower UCK2 mRNA levels. CA1: 
hippocampal cornus ammon 1; EC: entorhinal cortex; DG: dentate gyrus; LC: locus ceruleus.  
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Supplementary Tables 
 
Supplementary Table 1. Brain expression of genes for the de novo pyrimidine biosynthesis pathway, and UCK2, from 
different animal species. 
Animals CAD DHODH UMPS UCK2 
Chlorocebus sabaeusa,b,c 4-32 1-10 6-24 5-18 
Macaca mulattaa,b,c 14-15 14-18 6 16-29 
Papio anubisa,b,c 8-13 5-9 9-14 13-32 
Mus musculusa,b 6-27 6-10 11-30 13-71 
Rattus norvegicusa,b 4-11 4-6 22-34 11-26 
Bos taurusa,b 8-9 - 6 42 
Equus caballusa,b 6 7 53 26 
Ovis ariesa,b 1 4 4 7 
Monodelphis domesticaa,d 23 32 39 22 
Gallus galluse 8-9 6-10 8-12   62-79 
Xenopus tropicalisf 33 25 18 12 
Expression is reported as number of transcripts of a particular gene per million molecules in the RNA-seq sample. a, mammal; 




Please browse Full Text version to see the data of Supplementary Table 2. 
 
Supplementary Table 2. Summary of cases used for mRNA expression studies. CA1: hippocampal cornus ammon 1; DG: 
dentate gyrus; EC: entorhinal cortex; LC: locus ceruleus. CHPC: Clinical and HistoPathological Controls. RIN: RNA integrity number. F: female; M: 
male. PMD: post-mortem delay. DHODH and UCK2 mRNA levels have been normalized to 103 GAPDH mRNAs. The CHPC MT-CO1 / 18S ratio mean 
values have been considered 100 %. 
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Supplementary Table 3. Expression of genes for the de novo pyrimidine biosynthesis pathway, UCK2 and GAPDH, in 
different regions from human adult brain.  
Brain region CAD DHODH UMPS UCK2 GAPDH Sex-Age STUDY 
Amygdala 1 6 11   F60, F76 68 FANTOM 
Brain 1 4 7   M18 68 FANTOM 
Brain meninx 1 2 8   F82 68 FANTOM 
Caudate nucleus 3 3 13   F60, F76 68 FANTOM 
Cerebellum - 1 11   F60, F76 68 FANTOM 
Diencephalon 0.7 4 12   M26(29) 68 FANTOM 
Dorsal thalamus 1 4 11   F60, F76 68 FANTOM 
Dura mater 2 4 13   F59 68 FANTOM 
Globus pallidus 2 5 11   F60, F76 68 FANTOM 
Hippocampal formation 2 4 10   F60, F76 68 FANTOM 
Locus ceruleus 1 4 9   F60, F76 68 FANTOM 
Medulla oblongata 0.9 5 10   F60, F76 68 FANTOM 
Middle frontal gyrus 1 3 7   F60, F76 68 FANTOM 
Middle temporal gyrus 2 3 11   F60, F76 68 FANTOM 
Occipital cortex 2 4 10   F60, F76 68 FANTOM 
Occipital lobe 3 3 8   M27 68 FANTOM 
Olfactory apparatus 1 3 8   F87 68 FANTOM 
Parietal lobe 0.9 3 9   F60, F76 68 FANTOM 
Pineal body 1 3 11   F60, F76 68 FANTOM 
Pituitary gland 0.9 3 14   F60, F76 68 FANTOM 
Putamen 3 4 12   F60 68 FANTOM 
Spinal cord 3 3 13   F60, F76 68 FANTOM 
Substantia nigra 0.5 1 8   F60, F76 68 FANTOM 
        













        
Cerebellum 20 5 7 23 1,484 F, M KAESSMANN 
Frontal lobe 17 5 5 15 2,332 F, M KAESSMANN 
Prefrontal cortex 10 3 5 16 1,891 M KAESSMANN 
Temporal lobe 20 4 4 12 2,975 M KAESSMANN 
Expression is shown as the number of transcripts of a particular gene per million molecules in the RNA-seq sample. Four 
different studies have been considered. F: female; M: male; age in years.  
